Clinical Scorecard: Pregnancy After CAR T Shows Early Promise
At a Glance
| Category | Detail |
|---|---|
| Condition | Pregnancy after CD19-directed CAR T-cell therapy for autoimmune disease |
| Key Mechanisms | CD19-directed CAR T-cell therapy targets disease-associated B cells; prolonged maternal B-cell depletion may raise questions about fetal or newborn effects. |
| Target Population | Patients with autoimmune disease who become pregnant after CAR T-cell therapy |
| Care Setting | Pregnancy and postpartum follow-up after CAR T-cell treatment; evidence is from an early report of 14 pregnancies in 13 patients. |
Key Highlights
- The report included 14 pregnancies in 13 patients previously treated with CAR T-cell therapy for autoimmune disease.
- No autoimmune disease flares were reported during pregnancy; all but one patient remained drug-free or received only prophylactic hydroxychloroquine.
- Eight healthy babies had been born, five pregnancies were ongoing, and one pregnancy was electively terminated for reasons unrelated to autoimmune disease.
- No CAR T cells were detected in newborns; CD19-positive B-cell counts and IgG levels were within normal ranges.
- Infant follow-up ranged from 1 to 18 months, with normal development reported in all eight infants.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- The researchers called for pregnancy registries to capture additional outcomes after CAR T-cell therapy.
- Further studies were called for to examine the effects of lymphodepletion and CAR T-cell treatment on fertility.
Risks
- The report notes questions about autoimmune disease relapse without ongoing immunosuppression and possible fetal or newborn effects of prolonged maternal B-cell depletion.
- One patient developed preeclampsia with changes in proteinuria and renal-retention variables; renal biopsy showed no active lupus nephritis.
Patient & Prescribing Data
Thirteen patients with autoimmune disease: eight with systemic lupus erythematosus, two with systemic sclerosis, and one each with idiopathic inflammatory myositis, systemic sclerosis-rheumatoid arthritis overlap syndrome, or antiphospholipid syndrome.
All pregnancies occurred spontaneously. Time from CAR T-cell therapy to conception ranged from 1 to 42 months. All but one patient remained drug-free or received only prophylactic hydroxychloroquine.
Clinical Best Practices
- Interpret the findings as early evidence from a small case series; the report included 14 pregnancies in 13 patients.
- Consider the reported maternal and neonatal outcomes in the context of the limited follow-up, which ranged from 1 to 18 months for infants.
- Support further outcome collection through pregnancy registries and research on fertility after lymphodepletion and CAR T-cell treatment.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
